• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

0.2%溴莫尼定与0.5%噻吗洛尔对高眼压症患者视网膜神经纤维层厚度影响的比较:一项前瞻性、非盲法研究。

Comparison of the effects of brimonidine 0.2% and timolol 0.5% on retinal nerve fiber layer thickness in ocular hypertensive patients: a prospective, unmasked study.

作者信息

Tsai Jen-Chia, Chang Hsueh-Wen

机构信息

Department of Ophthalmology, Chang Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China.

出版信息

J Ocul Pharmacol Ther. 2005 Dec;21(6):475-82. doi: 10.1089/jop.2005.21.475.

DOI:10.1089/jop.2005.21.475
PMID:16386089
Abstract

AIMS

The aim of this study was to compare the effects of brimonidine and timolol on retinal nerve fiber layer (RNFL) thickness in ocular hypertensive patients.

METHODS

This was a prospective, comparative, and unmasked study. For 12 months, 38 eyes of 19 patients with primary open-angle glaucoma received brimonidine tartrate 0.2%, and 40 eyes of 20 patients received timolol maleate 0.5%. Intraocular pressure (IOP) was measured every 2 months, and RNFL thickness was assessed using Scanning laser polarimetry (GDx) at baseline and at 12 months.

RESULTS

Mean IOP reduction was similar in both groups. Within each treatment group, the RNFL thickness for ellipse average (P = 0.004), superior (P = 0.035), temporal (P = 0.003), inferior (P < 0.0001), and nasal averages (P = 0.044) were significantly decreased from baseline in timolol at 12 months. However, the RNFL thickness for ellipse average and four quadrants showed no significant change from baseline in brimonidine. The between-group difference in RNFL change showed a significant reduction for ellipse average (P = 0.02), temporal (P = 0.005), and inferior averages (P = 0.016) following timolol therapy, as compared to brimonidine.

CONCLUSIONS

There appear to be less progression for RNFL damage following brimonidine 0.2% therapy compared to timolol 0.5% in ocular hypertensive patients over 1 year. This finding does not correlate with IOP reduction.

摘要

目的

本研究旨在比较溴莫尼定和噻吗洛尔对高眼压患者视网膜神经纤维层(RNFL)厚度的影响。

方法

这是一项前瞻性、对比性、非盲法研究。19例原发性开角型青光眼患者的38只眼接受0.2%酒石酸溴莫尼定治疗12个月,20例患者的40只眼接受0.5%马来酸噻吗洛尔治疗。每2个月测量眼压(IOP),并在基线和12个月时使用扫描激光偏振仪(GDx)评估RNFL厚度。

结果

两组平均眼压降低情况相似。在每个治疗组中,噻吗洛尔治疗12个月时,椭圆平均值(P = 0.004)、上方(P = 0.035)、颞侧(P = 0.003)、下方(P < 0.0001)和鼻侧平均值(P = 0.044)的RNFL厚度与基线相比均显著降低。然而,溴莫尼定治疗后椭圆平均值和四个象限的RNFL厚度与基线相比无显著变化。与溴莫尼定相比,噻吗洛尔治疗后椭圆平均值(P = 0.02)、颞侧(P = 0.005)和下方平均值(P = 0.016)的RNFL变化组间差异有显著降低。

结论

在高眼压患者中,0.2%溴莫尼定治疗1年后RNFL损伤进展似乎比0.5%噻吗洛尔少。这一发现与眼压降低无关。

相似文献

1
Comparison of the effects of brimonidine 0.2% and timolol 0.5% on retinal nerve fiber layer thickness in ocular hypertensive patients: a prospective, unmasked study.0.2%溴莫尼定与0.5%噻吗洛尔对高眼压症患者视网膜神经纤维层厚度影响的比较:一项前瞻性、非盲法研究。
J Ocul Pharmacol Ther. 2005 Dec;21(6):475-82. doi: 10.1089/jop.2005.21.475.
2
Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.青光眼或高眼压症患者每日两次使用0.2%酒石酸溴莫尼定-0.5%噻吗洛尔固定复方疗法与噻吗洛尔或酒石酸溴莫尼定单药治疗的比较:一项为期12个月的随机试验
Arch Ophthalmol. 2006 Sep;124(9):1230-8. doi: 10.1001/archopht.124.9.1230.
3
Comparison of the efficacy and safety of dorzolamide 2% when added to brimonidine 0.2% or timolol maleate 0.5% in patients with primary open-angle glaucoma.在原发性开角型青光眼患者中,比较2%多佐胺添加到0.2%溴莫尼定或0.5%马来酸噻吗洛尔中的疗效和安全性。
J Ocul Pharmacol Ther. 2005 Feb;21(1):68-74. doi: 10.1089/jop.2005.21.68.
4
An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.一项为期八周的多中心、随机、介入性、开放标签的4期平行对照研究,比较0.5%马来酸噻吗洛尔/0.2%酒石酸溴莫尼定固定组合与0.5%马来酸噻吗洛尔/2%多佐胺固定组合对眼压升高患者的疗效和耐受性。
J Glaucoma. 2008 Dec;17(8):674-9. doi: 10.1097/IJG.0b013e318168f008.
5
Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability.多佐胺/噻吗洛尔复方制剂与溴莫尼定和噻吗洛尔联合给药的比较:疗效和耐受性的六个月对比
Ophthalmology. 2003 Mar;110(3):615-24. doi: 10.1016/S0161-6420(02)01900-0.
6
Brimonidine 0.2% vs unoprostone 0.15% both added to timolol maleate 0.5% given twice daily to patients with primary open-angle glaucoma or ocular hypertension.将0.2%的溴莫尼定与0.15%的乌诺前列酮分别添加到0.5%的马来酸噻吗洛尔中,每天给原发性开角型青光眼或高眼压症患者用药两次。
Eye (Lond). 2005 Jan;19(1):35-40. doi: 10.1038/sj.eye.6701392.
7
[Phase III clinical trial of brimonidine in patients with primary open-angle glaucoma and ocular hypertension--comparison of the effects of brimonidine monotherapy versus timolol monotherapy, or combination brimonidine/prostaglandins therapy versus combination placebo/prostaglandins therapy].溴莫尼定治疗原发性开角型青光眼和高眼压症患者的III期临床试验——溴莫尼定单药治疗与噻吗洛尔单药治疗效果比较,或溴莫尼定/前列腺素联合治疗与安慰剂/前列腺素联合治疗效果比较
Nippon Ganka Gakkai Zasshi. 2012 Oct;116(10):955-66.
8
Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study.固定剂量组合溴莫尼定-噻吗洛尔与拉坦前列素治疗青光眼和高眼压症:12 周随机比较研究。
Curr Med Res Opin. 2012 May;28(5):781-8. doi: 10.1185/03007995.2012.681036. Epub 2012 Apr 25.
9
A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group.溴莫尼定每日两次治疗青光眼和高眼压症的1年研究。一项对照、随机、多中心临床试验。慢性溴莫尼定研究组。
Arch Ophthalmol. 1997 Jul;115(7):847-52. doi: 10.1001/archopht.1997.01100160017002.
10
The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension.拉坦前列素、溴莫尼定以及噻吗洛尔与多佐胺固定复方制剂对青光眼或高眼压症患者昼夜眼压的影响。
Arch Ophthalmol. 2003 Apr;121(4):453-7. doi: 10.1001/archopht.121.4.453.

引用本文的文献

1
Advances in Neuroprotection in Glaucoma: Pharmacological Strategies and Emerging Technologies.青光眼神经保护的进展:药理学策略与新兴技术
Pharmaceuticals (Basel). 2024 Sep 25;17(10):1261. doi: 10.3390/ph17101261.
2
The Role of Retinal Ganglion Cell Structure and Function in Glaucoma.视网膜神经节细胞结构和功能在青光眼中的作用。
Cells. 2023 Dec 8;12(24):2797. doi: 10.3390/cells12242797.
3
Neuroprotection in Glaucoma: Basic Aspects and Clinical Relevance.青光眼的神经保护:基础方面与临床相关性
J Pers Med. 2022 Nov 10;12(11):1884. doi: 10.3390/jpm12111884.
4
A longitudinal comparison in cynomolgus macaques of the effect of brimonidine on optic nerve neuropathy using diffusion tensor imaging magnetic resonance imaging and spectral domain optical coherence tomography.使用扩散张量成像磁共振成像和光谱域光学相干断层扫描对食蟹猴进行溴莫尼定对视神经病变影响的纵向比较。
Heliyon. 2021 Apr 6;7(4):e06701. doi: 10.1016/j.heliyon.2021.e06701. eCollection 2021 Apr.
5
Neuroprotective Strategies for Retinal Ganglion Cell Degeneration: Current Status and Challenges Ahead.神经保护策略治疗视网膜神经节细胞变性:现状与挑战。
Int J Mol Sci. 2020 Mar 25;21(7):2262. doi: 10.3390/ijms21072262.
6
Topical Curcumin Nanocarriers are Neuroprotective in Eye Disease.局部姜黄素纳米载体在眼病中具有神经保护作用。
Sci Rep. 2018 Jul 23;8(1):11066. doi: 10.1038/s41598-018-29393-8.
7
A Masked, Randomized, Phase 3 Comparison of Triple Fixed-Combination Bimatoprost/Brimonidine/Timolol versus Fixed-Combination Brimonidine/Timolol for Lowering Intraocular Pressure.比马前列素/溴莫尼定/噻吗洛尔三联固定组合与溴莫尼定/噻吗洛尔固定组合降低眼压的3期随机双盲对照研究
J Ophthalmol. 2017;2017:4586763. doi: 10.1155/2017/4586763. Epub 2017 Sep 19.
8
Neuroprotection in Glaucoma.青光眼的神经保护
J Ophthalmic Vis Res. 2016 Apr-Jun;11(2):209-20. doi: 10.4103/2008-322X.183923.
9
Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation.体内大鼠模型和视网膜整装片制备中的青光眼诱导手术
J Vis Exp. 2016 Mar 12(109):53831. doi: 10.3791/53831.
10
A pharmacoeconomic analysis to determine the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine 0.2% eye drops in patients of primary open-angle glaucoma/ocular hypertension.一项药物经济学分析,以确定0.03%比马前列素滴眼液和0.2%溴莫尼定滴眼液在原发性开角型青光眼/高眼压症患者中的相对成本效益。
Indian J Ophthalmol. 2014 Dec;62(12):1136-40. doi: 10.4103/0301-4738.149134.